HDM-SPIRE

Drug Profile

HDM-SPIRE

Alternative Names: Antiallergy vaccine house dust mite - Circassia; House dust mite allergy immunotherapy - Circassia; House dust mite allergy vaccine - Circassia; House dust mite SPIRE; ToleroMune HDM; ToleroMune house dust mite

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Circassia
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 13 Apr 2017 Circassia completes a phase II trial in Allergic rhinoconjunctivitis in USA, Canada, France, Germany, Italy, Latvia, Lithuania, Netherlands, South Africa, Spain (NCT02150343)
  • 28 Jul 2015 Phase-II development is ongoing in Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA
  • 01 Sep 2014 Phase-II clinical trials in Allergic rhinoconjunctivitis in USA, Germany, Italy and the Netherlands (Intradermal) (NCT02150343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top